IRVINE, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company
dedicated to aesthetic medicine, today announced that it will release 2018 second quarter financial results before the market open
on Thursday, August 2, 2018.
Management will host a conference call and live webcast to discuss the Company's financial results at 8:30 a.m. ET that same
day. A question and answer session will follow management remarks.
The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international
callers. The conference ID is 9738939.
A replay of the call will be available following its completion through August 9, 2018. To access the replay, dial (855)
859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 9738939.
A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30
days following the completion of the call.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in
aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a
900 kDa purified botulinum toxin type A complex that is being evaluated for the treatment of moderate to severe glabellar
lines.
Evolus Contacts:
Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com
Media:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com
